Member Info for square10

"bn is merely for Dox, Avacta are after the entire chemo market. Success in AVA6k would give it high probability of success across other drugs whilst DDDD-which I hold- are only ever likely to see a small fraction of their target market

However DDDD treatments are never going to 'cure' cancer or likely be primary treatments but part of combination therapies. Avacta's tech if it works, addresses a far larger market

Well the signaled fundraise at ODX is obviously being used as the hammer on the price but in the cold light of day is nonsensical. I wonder if the panic/forced selling will be the signal for Jupiter to close, with no fundraise required here and Company far from a covid play. Soon I hope!!

wyn- a premium to current price, when you could buy in size as opposed to now where buying in size would be difficult especially if other buyers are competing.

I do think Friday will be the RNS day and I wouldn't 100% discount a near term fund raise but at a premium to current price. The target audience will be being educated as to what to look for IMO and will happily take part. That may not be immediate but in coming weeks. That is pure guess work, of course. Fingers crossed for us holders.